Cas no 74815-57-9 (Gastrin releasing peptide, porcine)
Gastrin releasing peptide, porcine Chemical and Physical Properties
Names and Identifiers
-
- Gastrin-releasingpeptide (swine) (9CI)
- Gastrin Releasing Peptide porcine
- ALA-PRO-VAL-SER-VAL-GLY-GLY-GLY-THR-VAL-LEU-ALA-LYS-MET-TYR-PRO-ARG-GLY-ASN-HIS-TRP-ALA-VAL-GLY-HIS-LEU-MET-NH2
- Gastrin Releasing Peptide porcineGastrin Releasing Peptide
- GASTRIN RELEASING PEPTIDE, PROCINE
- GRP (porcine)
- Gastrin-releasing peptide (pig)
- CID 16132336
- Gastrin releasing peptide, porcine
- H-Ala-Pro-Val-Ser-Val-Gly-Gly-Gly-Thr-Val-Leu-Ala-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2
-
- Inchi： 1S/C126H198N38O31S2/c1-62(2)44-83(155-121(191)102(67(11)12)162-123(193)103(71(16)166)158-98(173)56-138-94(169)54-137-95(170)55-140-120(190)100(65(7)8)160-116(186)90(59-165)157-122(192)101(66(9)10)161-118(188)92-31-24-40-163(92)124(194)68(13)128)110(180)144-69(14)105(175)149-81(28-21-22-38-127)108(178)150-82(37-43-197-18)109(179)156-89(46-72-32-34-76(167)35-33-72)125(195)164-41-25-30-91(164)117(187)151-80(29-23-39-135-126(131)132)107(177)139-57-96(171)147-88(50-93(129)168)115(185)154-87(49-75-53-134-61-143-75)114(184)153-85(47-73-51-136-78-27-20-19-26-77(73)78)111(181)145-70(15)106(176)159-99(64(5)6)119(189)141-58-97(172)146-86(48-74-52-133-60-142-74)113(183)152-84(45-63(3)4)112(182)148-79(104(130)174)36-42-196-17/h19-20,26-27,32-35,51-53,60-71,79-92,99-103,136,165-167H,21-25,28-31,36-50,54-59,127-128H2,1-18H3,(H2,129,168)(H2,130,174)(H,133,142)(H,134,143)(H,137,170)(H,138,169)(H,139,177)(H,140,190)(H,141,189)(H,144,180)(H,145,181)(H,146,172)(H,147,171)(H,148,182)(H,149,175)(H,150,178)(H,151,187)(H,152,183)(H,153,184)(H,154,185)(H,155,191)(H,156,179)(H,157,192)(H,158,173)(H,159,176)(H,160,186)(H,161,188)(H,162,193)(H4,131,132,135)/t68-,69-,70-,71+,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,99-,100-,101-,102-,103-/m0/s1
- InChI Key： GLCDCQPXUJKYKQ-GZDVRPNBSA-N
- SMILES： S(C)CC[C@@H](C(N[C@@H](CC1C=CC(=CC=1)O)C(N1CCC[C@H]1C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](C)C(N[C@H](C(NCC(N[C@@H](CC1=CN=CN1)C(N[C@H](C(N[C@H](C(N)=O)CCSC)=O)CC(C)C)=O)=O)=O)C(C)C)=O)=O)CC1=CNC2C=CC=CC1=2)=O)CC1=CN=CN1)=O)CC(N)=O)=O)=O)CCCNC(=N)N)=O)=O)=O)NC([C@H](CCCCN)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](C(C)C)NC([C@H]([C@@H](C)O)NC(CNC(CNC(CNC([C@H](C(C)C)NC([C@H](CO)NC([C@H](C(C)C)NC([C@@H]1CCCN1C([C@H](C)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Computed Properties
- Exact Mass: 2803.45000
- Hydrogen Bond Donor Count: 37
- Hydrogen Bond Acceptor Count: 38
- Heavy Atom Count: 197
- Rotatable Bond Count: 86
- Complexity: 6310
- XLogP3: -3.3
- Topological Polar Surface Area: 1120
Experimental Properties
- Density: 1.46±0.1 g/cm3 (20 oC 760 Torr),
- PSA: 1123.58000
- LogP: 3.34950
Gastrin releasing peptide, porcine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | G71300-1mg |
GASTRIN RELEASING PEPTIDE, PORCINE |
74815-57-9 | 97% | 1mg |
￥2748.0 | 2023-09-07 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajci17950-1mg |
GRP (porcine) |
74815-57-9 | 98% | 1mg |
￥2721.00 | 2023-09-09 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajci17950-500ug |
GRP (porcine) |
74815-57-9 | 98% | 500ug |
￥1764.00 | 2023-09-09 | |
| LKT Labs | G0182-1mg |
Gastrin Releasing Peptide, pig |
74815-57-9 | ≥98% | 1mg |
$584.00 | 2024-05-21 | |
| A2B Chem LLC | AH49182-1mg |
GASTRIN RELEASING PEPTIDE, PORCINE |
74815-57-9 | 1mg |
$312.00 | 2024-04-19 | ||
| A2B Chem LLC | AH49182-10mg |
GASTRIN RELEASING PEPTIDE, PORCINE |
74815-57-9 | 10mg |
$699.00 | 2024-04-19 | ||
| SHENG KE LU SI SHENG WU JI SHU | sc-495870-1mg |
GRP, |
74815-57-9 | 1mg |
￥1617.00 | 2023-09-05 | ||
| TargetMol Chemicals | TP2026-1mg |
GRP (porcine) |
74815-57-9 | 1mg |
￥ 2440 | 2024-07-20 | ||
| AAPPTec | P001725-1mg |
Gastrin Releasing Peptide, porcine |
74815-57-9 | 1mg |
$180.00 | 2024-07-19 | ||
| AAPPTec | P001725-5mg |
Gastrin Releasing Peptide, porcine |
74815-57-9 | 5mg |
$624.00 | 2024-07-19 |
Gastrin releasing peptide, porcine Related Literature
-
Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
-
2. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
-
J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
-
Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
Additional information on Gastrin releasing peptide, porcine
Gastrin releasing peptide, porcine (CAS No. 74815-57-9): A Comprehensive Overview of Its Biological Significance and Recent Research Developments
The compound Gastrin releasing peptide, porcine (CAS No. 74815-57-9) is a biologically active peptide that has garnered significant attention in the field of pharmaceutical and biomedical research. Gastrin releasing peptide, porcine, is a synthetic form of the naturally occurring neuropeptide that plays a crucial role in the regulation of gastrointestinal functions. This introduction aims to provide a detailed exploration of the biological significance of this compound, its pharmacological properties, and the latest advancements in research involving Gastrin releasing peptide, porcine.
Neuropeptides are a class of signaling molecules that play essential roles in various physiological processes. Among these, Gastrin releasing peptide, porcine, is known for its involvement in the stimulation of gastric acid secretion and the regulation of appetite. The synthetic version available under CAS No. 74815-57-9 has been widely used in laboratory settings for studying the mechanisms underlying gastrointestinal motility and secretion.
The structure of Gastrin releasing peptide, porcine consists of 31 amino acids arranged in a specific sequence that determines its biological activity. This sequence is highly conserved across species, indicating its fundamental importance in physiological processes. The synthetic production of this peptide has enabled researchers to conduct detailed studies on its interactions with target receptors and its effects on cellular signaling pathways.
In recent years, significant progress has been made in understanding the therapeutic potential of Gastrin releasing peptide, porcine. One area of focus has been its role in cancer research. Studies have shown that this peptide can induce apoptosis in certain cancer cell lines, making it a promising candidate for developing targeted therapies. Additionally, research has explored its potential in treating gastrointestinal disorders such as peptic ulcers and irritable bowel syndrome (IBS).
The pharmacological properties of Gastrin releasing peptide, porcine, have also been investigated for their potential in managing metabolic diseases. Emerging evidence suggests that this peptide may influence glucose homeostasis and insulin sensitivity, making it a candidate for therapeutic intervention in diabetes mellitus. These findings highlight the broad therapeutic scope of Gastrin releasing peptide, porcine.
Advances in biotechnology have enabled the large-scale production of high-purity Gastrin releasing peptide, porcine, which has facilitated more comprehensive clinical studies. These studies aim to evaluate the safety and efficacy of this compound in various therapeutic settings. The availability of synthetic peptides with CAS No. 74815-57-9 has significantly enhanced the ability of researchers to conduct controlled experiments and draw more accurate conclusions about their biological effects.
The development of novel drug delivery systems has also played a crucial role in enhancing the therapeutic potential of Gastrin releasing peptide, porcine. Techniques such as nanoparticle encapsulation and targeted release have improved the bioavailability and specificity of this peptide, thereby increasing its efficacy in treating target conditions. These innovations are paving the way for new treatment modalities based on Gastrin releasing peptide, porcine.
In conclusion, Gastrin releasing peptide, porcine (CAS No. 74815-57-9) is a multifaceted compound with significant implications for both basic research and clinical applications. Its role in regulating gastrointestinal functions and its potential therapeutic applications in cancer and metabolic diseases underscore its importance in modern biomedical research. As research continues to uncover new insights into its mechanisms and applications, Gastrin releasing peptide, porcine is poised to play an increasingly vital role in pharmaceutical development.
74815-57-9 (Gastrin releasing peptide, porcine) Related Products
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
- 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
- 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
